Busy. Please wait.
or

show password
Forgot Password?

Don't have an account?  Sign up 
or

Username is available taken
show password

why


Make sure to remember your password. If you forget it there is no way for StudyStack to send you a reset link. You would need to create a new account.
We do not share your email address with others. It is only used to allow you to reset your password. For details read our Privacy Policy and Terms of Service.


Already a StudyStack user? Log In

Reset Password
Enter the associated with your account, and we'll email you a link to reset your password.

Remove ads
Don't know
Know
remaining cards
Save
0:01
To flip the current card, click it or press the Spacebar key.  To move the current card to one of the three colored boxes, click on the box.  You may also press the UP ARROW key to move the card to the "Know" box, the DOWN ARROW key to move the card to the "Don't know" box, or the RIGHT ARROW key to move the card to the Remaining box.  You may also click on the card displayed in any of the three boxes to bring that card back to the center.

Pass complete!

"Know" box contains:
Time elapsed:
Retries:
restart all cards




share
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.

  Normal Size     Small Size show me how

Meds for Depression

MEDICATIONS AFFECTING THE NERVOUS SYSTEM

QuestionAnswer
DEPRESSION IS WHAT KIND OF DISORDER A MOOD/AFFECTIVE
RELIEF OF SYMPTOMS OF DEPRESSION WITH ANTI-DEPRESSANT THERAPY CAN TAKE HOW LONG 1-3 WEEKS
WHEN CAN YOU EXPECT THE FULL BENEFITS OF ANTI-DEPRESSANT THERAPY TO TAKE PLACE 2-3 MONTHS
WHAT ARE THE FOUR MAIN GROUPS OF ANTI-DEPRESSANT MEDICATIONS TCA'S/TRICYCLIC ANTI-DEPRESSANTS SSRI'S/SELECTIVE SEROTONIN REUPTAKE INHIBITORS MOAI'S/MONOAMINE OXIDASE INHIBITORS ATYPICAL ANTIDEPRESSANTS
WHAT MEDICATIONS ARE UNDER THE CLASSIFICATION OF TCA'S AMITRIPTYLINE/ELAVIL IMIPRAMINE/TOFRANIL DOXEPIN/SINEQUAN NORTRIPTYLINE/AVENTYL TRIMIPRAMINE/SURMONTIL
WHAT IS THE EXPECTED PHARMACOLOGICAL ACTION OF TCA'S BLOCK REUPTAAKE OF NOREPINEPHRINE AND SEROTONIN IN THE SYNAPTIC SPACE THEREBY INTENSIFYING THE EFFECTS OF THESE NEUROTRANSMITTERS
WHAT ARE THE THERAPEUTIC EFFECTS OF TCA'S DEPRESSION DEPRESSIVE EPISODES OF BIPOLAR DISORDER CHRONIC PAIN ENURESIS
WHAT ARE THE SIDE EFFECTS OF USING TCA'S ORTHOSTATIC HYPOTENSION ANTICHOLINERGIC EFFECTS SEDATION TOXICITY DECREASED SEIZURE THRESHOLD EXCESSIVE SWEATING
WHAT ARE THE ANTICHOLINERGIC EFFECTS OF TCA'S DRY MOUTH BLURRED VISION PHOTOPHOBIA URINARY HESITANCY OR RETENTION CONSTIPATION TACHYCARDIA
WHAT KIND OF TOXICITY RESULTS FROM USING TCA'S CHOLINERGIC BLOCKADE AND CARDIAC TOXICITY EVIDENCED BY DYSRHYTHMIAS MENTAL CONFUSION AGITATION FOLLOWED BY SEIZURES COMA POSSIBLE DEATH
TCA'S ARE A PREGNANCY CATEGORY RISK? C
TCA'S ARE CONTRAINDICATED IN CLIENTS THAT ? HAVE SEIZURE DISORDERS
TCA'S ARE USED CAUTIOUSLY IN CLIENTS WITH CORONARY ARTERY DISEASE DIABETES LIVER DISORDER KIDNEY DISORDER RESPIRATORY DISORDER URINARY RETENTION AND OBSTRUCTION ANGLE-CLOSURE GLAUCOMA BENIGN PROSTATIC HYPERTROPHY HYPERTHYROIDISM
INTERACTIONS WITH TCA'S INCLUDE MAOI'S AND ST JOHNS WORT = SEROTONIN SYNDROME ANTIHISTAMINES = ADDITIVE ANTICHOLINERGIC EFFECTS TCA'S DECREASE EPHEDRINE, AMPHETAMINE EFFECTS ALCOHOL, ANTIHISTAMINES, BENZO'S, OPIOIDS = ADDED CNS DEPRESSANT INCREASED EFFECTS OF EPINEPHRINE, DOPAMINE
MEDICATIONS CLASSIFIED AS SSRI'S ARE FLUOXETINE/PROZAC CITALOPRAM/CELEXA ESCITALOPRAM/LEXAPRO PAROXETINE/PAXIL SERTRALINE/ZOLOFT
WHAT IS THE EXPECTED PHARMACOLOGICAL ACTION OF SSRI'S SELECTIVELY BLOCK REUPTAKE OF THE MONOAMINE NEUROTRANSMITTER SEROTONIN IN THE SYNAPTIC SPACE THEREBY INTENSIFYING THE EFFECTS OF SEROTONIN
THERAPEUTIC USES OF SSRI'S ARE MAJOR DEPRESSION OCD BULIMIA NERVOSA PMDD PANIC DISORDER PTSD
SIDE EFFECTS OF SSRI'S ARE SEXUAL DYSFUNCTION CNS STIMULATION WEIGHT LOSS (EARLY IN THERAPY) WEIGHT GAIN (IN LATER THERAPY) SEROTONIN SYNDROME WITHDRAWAL SYMPTOMS HYPONATREMIA RASH SLEEPINESS FAINTNESS LIGHTHEADEDNESS GI BLEEDING BRUXISM
SEROTONIN SYNDROME MAY BEGIN WHEN 2-72 HOURS AFTER STARTING THERAPY AND MAY BE LETHAL
SIDE EFFECTS ASSOCIATED WITH SEROTONIN SYNDROME MENTAL CONFUSION DIFFICULTY CONCENTRATING FEVER AGITATION ANXIETY HALLUCINATIONS INCOORDINATION HYPERREFLEXIA DIAPHORESIS TREMORS
WITHDRAWAL SYMPTOMS ASSOCIATED WITH SSRI'S ARE HEADACHE NAUSEA VISUAL DISTURBANCES ANXIETY DIZZINESS TREMORS
FLUOXETINE IS A PREGNANCY RISK CATEGORY C
FLUOXETINE AND PAROXETINE MAY INCREASE THE RISKS OF WHAT BIRTH DEFECTS
SSRI'S ARE CONTRAINDICATED IN CLIENTS TAKING MAOI'S AND TCA'S
SSRI'S ARE USED CAUTIOUSLY IN CLIENTS WITH LIVER DYSFUNCTION RENAL DYSFUNCTION CARDIAC DISEASE SEIZURE DISORDERS DIABETES ULCERS HISTORY OF GI BLEEDING TAKING NSAIDS TAKING ANTI-COAGULANTS
MAOI'S AND ST JOHNS WORT INCREASE THE RISK OF SEROTONIN SYNDROME
FLUOXETINE CAN DISPLACE WARFARIN/COUMADIN FROM BOUND PROTEIN AND RESULT IN WHAT INCREASED WARFARIN LEVELS
FLUOXETINE CAN INCREASE THE LEVELS OF TCA'S AND WHAT LITHIUM
FLUOXETINE SUPPRESSES PLATELET AGGREGATION AND THUS INCREASES THE RISK OF BLEEDING WHEN USED WITH WHAT NSAID'S AND ANTI-COAGULANTS
MEDICATIONS IN THE MAOI CLASS ARE PHENELZINE/NARDIL ISOCARBOXAZID/MARPLAN TRANYLCYPROMINE/PARNATE SELEGILINE/EMSAM-TRANSDERMAL MAOI
THE EXPECTED PHARMACOLOGICAL ACTION OF MAOI'S IS BLOCK THE MAO-A IN THE BRAIN THEREBY INCREASING THE AMOUNT OF NOREPINEPHRINE, DOPAMINE, SEROTONIN AVAILABLE FOR TRANSMISSION OF IMPULSES THIS INTENSIFIES THE RESPONSE AND RELIEVES DEPRESSION
THERAPEUTIC USES OF MAOI'S ARE ATYPICAL DEPRESSION BULIMIA NERVOSA OCD
SIDE EFFECTS OF MAOI'S INCLUDE CNS STIMULATION ORTHOSTATIC HYPOTENSION HYPERTENSIVE CRISIS LOCAL RASH WITH TRANSDERMAL USE
WHAT ARE THE SPECIFIC SIDE EFFECTS ASSOCIATED WITH THE CNS STIMULATION ANXIETY AGITATION MANIA HYPOMANIA
WHAT CAUSES THE HYPERTENSIVE CRISIS ASSOCIATED WITH USE OF MAOI'S TYRAMINE CONTAINING FOODS
WHAT ARE THE SIDE EFFECTS OF HYPERTENSIVE CRISIS ASSOCIATED WITH THE USE OF TYRAMINES AND MAOI'S HEADACHE NAUSEA INCREASED HEART RATE INCREASED BLOOD PRESSURE
MAOI'S ARE PREGNANCY RISK CATEGORY C
MAOI'S ARE CONTRAINDICATED IN WHAT TYPE OF CLIENTS TAKING SSRI'S THOSE WITH PHEOCHROMOCYTOMA CARDIOVASCULAR DISEASE CEREBRAL VASCULAR DISEASE SEVERE RENAL INSUFFICENCY
MAOI'S ARE USED CAUTIOUSLY IN CLIENTS WITH DIABETES SEIZURE DISORDERS TAKING TCA'S
TRANSDERMAL SELEGILINE/EMSAM IS CONTRAINDICATED IN CLIENTS TAKING CARBAMAZEPINE/TEGRETOL OXCARBAZEPINE/TRILEPTAL WHICH MAY INCREASE THE BLOOD LEVELS OF THE MAOI
INTERACTIONS WITH MAOI'S INDIRECT ACTING SYMPATHOMIMETIC MEDICATIONS TCA'S SSRI'S MEPERIDINE/DEMEROL TYRAMINE RICH FOODS VASOPRESSORS
INDIRECT ACTING SYMPATHOMIMETIC MEDICATIONS PROMOTE THE RELEASE OF NOREPINEPHRINE AND CAN LEAD TO WHAT HYPERTENSIVE CRISIS
USE OF TCA'S AND MAOI'S CAN LEAD TO WHAT HYPERTENSIVE CRISIS
USE OF SSRI'S AND MAOI'S CAN LEAD TO WHAT SEROTONIN SYNDROME
ANTIHYPERTENSIVES AND MAOI'S HAVE A ADDITIVE WHAT EFFECT HYPOTENSIVE
MEPERIDINE/DEMEROL AND MAOI'SCAN LEAD TO WHAT HYPERPYREXIA
CONCURRENT USE OF VASOPRESSORS AND MAOI'S RESULT IN WHAT HYPERTENSION
WHAT ARE MEDICATIONS THAT ARE LISTED AS ATYPICAL ANTIDEPRESSANTS BUPROPRION HCL/WELLBUTRIN
WHAT IS THE EXPECTED PHARMACOLOGICAL ACTION OF ATYPICAL ANTI-DEPRESSANTS INHIBITING DOPAMINE UPTAKE
THERAPEUTIC USES OF ATYPICAL ANTI-DEPRESSANTS ARE TREATMENT OF DEPRESSION ALTERNATIVE TO SSRI'S FOR CLIENTS UNABLE TO TOLERATE SEXUAL DYSFUNCTION SIDE EFFECTS OF SSRI'S AID TO QUIT SMOKING PREVENTION OF SAD
SIDE EFFECTS OF ATYPICAL ANTI-DEPRESSANTS HEADACHE DRY MOUTH GI DISTRESS CONSTIPATION INCREASED HEART RATE NAUSEA RESTLESSNESS INSOMNIA SUPRESSION OF APPETITE WEIGHT LOSS SEIZURES
BUPROPRION HCL/WELLBUTRIN IS A PREGNANCY RISK CATEGORY WHAT B
ATYPICAL ANTI-DEPRESSANTS ARE CONTRAINDICATED IN CLIENTS THAT ARE TAKING MAOI'S
ATYPICAL ANTI-DEPRESSANTS ARE USED CAUTIOUSLY IN CLIENTS WHO HAVE SEIZURE DISORDERS
ATYPICAL ANTI-DEPRESSANTS INTERACT WITH MAOI'S AND INCREASE THE RISK OF TOXICITY
OTHER ATYPICAL ANTIDEPRESSANTS ARE VENLAFAXINE/EFFEXOR DULOXETINE/CYMBALTA (SNRI'S) MIRTAZAPINE/REMERON REBOXETINE/EDRONAX TRAZADONE/DESYREL
EFFEXOR AND CYMBALTA'S PHARMACOLOGICAL ACTION IS INHIBIT SEROTONIN AND NOREPINEPHRINE REUPTAKE THEREBY INCREASING THE AMOUNT OF THESE NEUROTRANSMITTERS AVAILABLE IN BRAIN IMPULSE TRANSMISSION
MIRTAZAPINE/REMERON'S PHARMACOLOGICAL ACTION INCREASE RELEASE OF SEROTONIN AND NOREPINEPHRINE AND THEREBY INCREASING THE AMOUNT OF NEUROTRANSMITTERS AVAILABLE FOR IMPULSE TRANSMISSION
REBOXETINE/EDRONAX'S PHARMACOLOGICAL ACTION SELECTIVELY INHIBITS THE REUPTAKE OF NOREPINEPHRINE THEREBY INCREASING THE AMOUNT OF NEUROTRANSMITTERS AVAILABLE FOR IMPULSE TRANSMISSION
TRAZADONE/DESYREL'S PHARMACOLOGICAL ACTION HAS MODERATE SELECTIVE BLOCKADE OF SEROTONIN RECEPTORS WHICH ALLOWS MORE SEROTONIN TO BE AVAILABLE FOR IMPULSE TRANSMISSION
Created by: nursebtanner